ReviewExperimental gerontology2018
Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.
Review in Experimental gerontology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Computer-Aided Decision Support Systems of Alzheimer's Disease Diagnosis - A Systematic Review.Current medical imaging · 2025Pooled it
- Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer's disease.Alzheimer's research & therapy · 2026Review
- Explainable Artificial Intelligence in Neuroimaging of Alzheimer's Disease.Diagnostics (Basel, Switzerland) · 2025Review
- Cutting-edge Strategies for Overcoming Therapeutic Barriers in Alzheimer's Disease.Current pharmaceutical design · 2025Review
- Neurodegenerative disorders, metabolic icebergs, and mitohormesis.Translational neurodegeneration · 2024Review
- Impact of the Ventricle Size on Alzheimer's Disease Progression: A Retrospective Longitudinal Study.Dementia and neurocognitive disorders · 2024Article
- Co-twin design in brain imaging-review on biomarkers of Alzheimer's disease.Cerebral cortex (New York, N.Y. : 1991) · 2023Review
- Review
- Gut Microbiota and Immunotherapy for Alzheimer's Disease.International journal of molecular sciences · 2022Review
- The relationship between body mass index and postoperative delirium.Brain and behavior · 2022Article
- Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation.Journal of Alzheimer's disease : JAD · 2022Article
- Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease.Alzheimer's research & therapy · 2021Article
- Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring.International journal of molecular sciences · 2021Review
- To Explore the Predictive Power of Visuomotor Network Dysfunctions in Mild Cognitive Impairment and Alzheimer's Disease.Frontiers in neuroscience · 2021Article
- Retinal Imaging in Alzheimer's Disease: In Search of the Holy Grail.Ophthalmology · 2020Article
- Neuroimaging Biomarkers for Alzheimer's Disease.Molecular neurodegeneration · 2019Review
- Delirium and Alzheimer disease: A proposed model for shared pathophysiology.International journal of geriatric psychiatry · 2019Article
- Radiomics: a novel feature extraction method for brain neuron degeneration disease usingTherapeutic advances in neurological disorders · 2019Article
- Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease.Acta neuropathologica · 2018Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
There is increasing evidence that a number of potentially informative biomarkers for Alzheimer disease (AD) can improve the accuracy of diagnosing this form of dementia, especially when used as a panel of diagnostic assays and interpreted in the context of neuroimaging and clinical data. Moreover, by combining the power of CSF biomarkers with neuroimaging techniques to visualize Aβ deposits (or neurodegenerative lesions), it might be possible to better identify individuals at greatest risk for developing MCI and converting to AD. The objective of this article was to review recent progress in selected imaging and chemical biomarkers for prediction, early diagnosis and progression of AD. We present our view point of a scenario that places CSF and imaging markers on the verge of general utility based on accuracy levels that already match (or even surpass) current clinical precision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.